Title : Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy - Fan_2023_Mol.Cell_83_3520 |
Author(s) : Fan Y , Gao Y , Nie L , Hou T , Dan W , Wang Z , Liu T , Wei Y , Wang Y , Liu B , Que T , Lei Y , Zeng J , Ma J , Wei W , Li L |
Ref : Mol Cell , 83 :3520 , 2023 |
Abstract :
Cyclic GMP-AMP synthase (cGAS) binds pathogenic and other cytoplasmic double-stranded DNA (dsDNA) to catalyze the synthesis of cyclic GMP-AMP (cGAMP), which serves as the secondary messenger to activate the STING pathway and innate immune responses. Emerging evidence suggests that activation of the cGAS pathway is crucial for anti-tumor immunity; however, no effective intervention method targeting cGAS is currently available. Here we report that cGAS is palmitoylated by ZDHHC9 at cysteines 404/405, which promotes the dimerization and activation of cGAS. We further identified that lysophospholipase-like 1 (LYPLAL1) depalmitoylates cGAS to compromise its normal function. As such, inhibition of LYPLAL1 significantly enhances cGAS-mediated innate immune response, elevates PD-L1 expression, and enhances anti-tumor response to PD-1 blockade. Our results therefore reveal that targeting LYPLAL1-mediated cGAS depalmitoylation contributes to cGAS activation, providing a potential strategy to augment the efficacy of anti-tumor immunotherapy. |
PubMedSearch : Fan_2023_Mol.Cell_83_3520 |
PubMedID: 37802025 |
Gene_locus related to this paper: human-LYPLAL1 |
Inhibitor | Lyplal1-IN-1 |
Gene_locus | human-LYPLAL1 |
Fan Y, Gao Y, Nie L, Hou T, Dan W, Wang Z, Liu T, Wei Y, Wang Y, Liu B, Que T, Lei Y, Zeng J, Ma J, Wei W, Li L (2023)
Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy
Mol Cell
83 :3520
Fan Y, Gao Y, Nie L, Hou T, Dan W, Wang Z, Liu T, Wei Y, Wang Y, Liu B, Que T, Lei Y, Zeng J, Ma J, Wei W, Li L (2023)
Mol Cell
83 :3520